XTL BIOXTL BIOXTL BIO

XTL BIO

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪81.53 M‬ILS
−0.0ILS
‪−6.57 M‬ILS
0.00ILS
‪1.12 B‬
Beta (1Y)
2.19
Employees (FY)
8
Change (1Y)
0
Revenue / Employee (1Y)
0.00ILS
Net income / Employee (1Y)
‪−226.25 K‬ILS

About XTL BIO


CEO
Shlomo Spokone Shalev
Website
Headquarters
Ramat Gan
Founded
1993
ISIN
IL0010854979
FIGI
BBG000GG7Z92
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of XTLB is 6.7 ILA — it has increased by 2.90% in the past 24 hours. Watch XTL BIO stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange XTL BIO stocks are traded under the ticker XTLB.
XTLB stock has risen by 2.90% compared to the previous week, the month change is a −21.11% fall, over the last year XTL BIO has showed a 109.38% increase.
XTLB reached its all-time high on Sep 2, 2008 with the price of 870.0 ILA, and its all-time low was 3.0 ILA and was reached on Aug 7, 2023. View more price dynamics on XTLB chart.
See other stocks reaching their highest and lowest prices.
XTLB stock is 7.58% volatile and has beta coefficient of 2.19. Track XTL BIO stock price on the chart and check out the list of the most volatile stocks — is XTL BIO there?
Today XTL BIO has the market capitalization of ‪89.06 M‬, it has increased by 12.73% over the last week.
Yes, you can track XTL BIO financials in yearly and quarterly reports right on TradingView.
XTL BIO is going to release the next earnings report on Dec 3, 2024. Keep track of upcoming events with our Earnings Calendar.
XTLB net income for the last quarter is ‪1.78 M‬ ILS, while the quarter before that showed ‪−1.09 M‬ ILS of net income which accounts for 263.72% change. Track more XTL BIO financial stats to get the full picture.
No, XTLB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 8.00 employees. See our rating of the largest employees — is XTL BIO on this list?
Like other stocks, XTLB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XTL BIO stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So XTL BIO technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating XTL BIO stock shows the sell signal. See more of XTL BIO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.